Targeting Adenosine for Cancer: Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9 th @ 10:30 am ET WESTPORT, Conn. , Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel
WESTPORT, Conn. , Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside
